Illumina Inc
NASDAQ:ILMN

Watchlist Manager
Illumina Inc Logo
Illumina Inc
NASDAQ:ILMN
Watchlist
Price: 135.21 USD 0.16%
Market Cap: 21.4B USD
Have any thoughts about
Illumina Inc?
Write Note

Illumina Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Illumina Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Illumina Inc
NASDAQ:ILMN
Revenue
$4.4B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
10%
Thermo Fisher Scientific Inc
NYSE:TMO
Revenue
$42.4B
CAGR 3-Years
3%
CAGR 5-Years
11%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Revenue
$21.2B
CAGR 3-Years
-9%
CAGR 5-Years
6%
CAGR 10-Years
1%
Mettler-Toledo International Inc
NYSE:MTD
Revenue
$3.8B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Revenue
$6.5B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
5%
IQVIA Holdings Inc
NYSE:IQV
Revenue
$15.3B
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
11%
No Stocks Found

Illumina Inc
Revenue Breakdown

Breakdown by Geography
Illumina Inc

Total Revenue: 4.5B USD
100%
Americas: 2.5B USD
56%
United States: 2.4B USD
52.4%
Europe: 1.1B USD
25.3%
Asia-Pacific, Middle East And Africa: 459m USD
10.2%
Greater China: 384m USD
8.5%
Show More
Show Less

Breakdown by Segments
Illumina Inc

Total Revenue: 4.5B USD
100%
Sequencing: 4.1B USD
91.3%
Product Revenue: 3.8B USD
84.1%
Consumables: 3.1B USD
68.5%
Service And Other Revenue: 717m USD
15.9%
Instruments: 704m USD
15.6%
Microarray: 392m USD
8.7%
Show More
Show Less

Illumina Inc
Glance View

Market Cap
21.5B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields. At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.

ILMN Intrinsic Value
144.84 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Illumina Inc's Revenue?
Revenue
4.4B USD

Based on the financial report for Sep 29, 2024, Illumina Inc's Revenue amounts to 4.4B USD.

What is Illumina Inc's Revenue growth rate?
Revenue CAGR 10Y
10%

Over the last year, the Revenue growth was -2%. The average annual Revenue growth rates for Illumina Inc have been 1% over the past three years , 5% over the past five years , and 10% over the past ten years .

Back to Top